Human Blood Collection to Serve as Negative Control for Validation of Circulating Tumor Cell Assay

Abramson Cancer Center at Penn Medicine1 个研究点分布在 1 个国家目标入组 43 人2014年11月1日

适应症Healthy

概览

阶段: 不适用
干预措施: 未指定
疾病 / 适应症: Healthy
发起方: Abramson Cancer Center at Penn Medicine
入组人数: 43
试验地点: 1
主要终点: blood count
状态: 已完成
最后更新: 3个月前

概览研究者入排标准结局指标研究点相似试验

概览

简要总结

Human blood will be collected to serve as control in validating clinical studies studying the detection and levels of circulating tumor cells and microvesicles in cancer patients. Targeted population is cancer-free 18-60 year old men and women. Volunteer selection will rely upon a short health questionnaire. About 20 mL blood will be collected from volunteers up to 20 different timepoints. The Procedure involves minimal risk of harm (eg discomfort, bruising) to the volunteer.

注册库

clinicaltrials.gov

开始日期

2014年11月1日

结束日期

2019年4月30日

最后更新

3个月前

研究类型

Observational

性别

All

研究者

发起方

Abramson Cancer Center at Penn Medicine

责任方

Sponsor

入排标准

入选标准

•Age range: 18-60 years old Gender: Male and Female

排除标准

•No previously diagnosed malignancy Age: It is important to obtain a healthy, cancer-free volunteer population to serve as negative controls for this detection assay.